Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy‐free, first‐line treatment for PD‐L1‐positive non‐small cell lung cancer-Reference-Cited by-同舟云学术

Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy‐free, first‐line treatment for PD‐L1‐positive non‐small cell lung cancer

Author:

Zhou Yixin¹²³^ORCID,Zhang Yaqiong¹²⁴,Guo Guifang¹²³,Cai Xiuyu¹²³,Yu Hui¹²³,Cai Yanyu¹²³,Zhang Bei¹²³,Hong Shaodong¹²⁵,Zhang Li¹²⁵

Affiliation:

1. State Key Laboratory of Oncology in South China Guangzhou China

2. Collaborative Innovation Center for Cancer Medicine Guangzhou China

3. Department of VIP region Sun Yat‐sen University Cancer Center Guangzhou China

4. Department of Radiotherapy Sun Yat‐sen University Cancer Center Guangzhou China

5. Department of Medical Oncology Sun Yat‐sen University Cancer Center Guangzhou China

Funder

National Key R&D Program of China

National Natural Science Funds of China

Outstanding Young Talents Program of Sun Yat-sen University Cancer Center

Central Basic Scientific Research Fund for Colleges-Young Teacher Training Program of Sun Yat-sen University

Science and Technology Program of Guangdong Province

Publisher

Wiley

Subject

Molecular Medicine,Medicine (miscellaneous)

Link

Reference11 articles.

5. Non‐Small Cell Lung Cancer (version 2.2020). National Comprehensive Cancer Network.https://www.nccn.org

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献